Showing 15 posts of 79 posts found.


Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment

June 22, 2023
Research and Development Asthma & COPD, Beclu, Lupin Healthcare, asthma, carbon neutral, inhaler

UK-based subsidiary of Lupin Limited, Lupin Healthcare, has announced the UK launch of its carbon neutral pressurised metered dose inhalers …


Asthma drug Dupixent sees positive results in child trials

May 18, 2021
Manufacturing and Production FDA, asthma

Data presented at the 2021 American Thoracic Society International Conference from a Phase III trial of Dupixent (dupilumab) in children …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

May 13, 2021
Amgen, AstraZeneca, asthma, asthma treatment, pharma, pharma news, severe asthma

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority across all primary and secondary …


GSK starts Phase III study for severe asthma treatment

March 18, 2021
GSK, asthma, phase III

GSK has announced today that the first patient has been dosed in part of their Phase III clinical trial investigating …

NICE recommends GSK’s Nucala for more asthma patients

December 18, 2020
Medical Communications GlaxoSmithKline, NICE, asthma, mepolizumab

NICE has today published final draft guidance recommending GlaxoSmithKline’s Nucala (mepolizumab) as an add-on treatment option for severe refractory eosinophilic …


Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma

September 8, 2020
Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma

New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …


US approves new generic to treat people suffering from respiratory conditions

August 25, 2020
Manufacturing and Production asthma, inhaler

The FDA has granted Lupin Ltd approval for their generic version of ProAir, which is used to prevent asthma symptoms …


AstraZeneca’s Fasenra has strong Phase 3 showing in severe eosinophilic asthma

August 6, 2020
Research and Development AstraZeneca, Fasenra, asthma

AstraZeneca took the opportunity at the American Thoracic Society 2020 Virtual International Conference to unveil positive new Phase 3b data …


Study launched to assess if asthma treatment ciclesonide can treat COVID-19

June 18, 2020
Business Services COVID-19, asthma, corona, coronavirus

Researchers at the University of Buffalo have launched a study to see if the steroid treatment ciclesonide could be effective …


The American Academy of Allergy, Asthma and Immunology calls off its 2020 Annual Meeting due to coronavirus concerns

March 10, 2020
Medical Communications, Research and Development Big Pharma, allergy, america, asthma, immunology

The American Academy of Allergy, Asthma and Immunology (AAAAI) has called off its 2020 Annual Meeting that was schedule to …


NICE shoots down Dupixent for severe asthma

March 9, 2020
Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …


Novartis abandons asthma drug after Phase 3 trial results

December 17, 2019
Manufacturing and Production Novartis, Novartis. R&D, asthma, novartis r&d

Novartis have said it is not going forward with a new asthma drug, as the treatement failed its Phase 3 …

Novartis pulls fevipiprant development in asthma following trial failure

December 16, 2019
Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure

Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …


European approval for two new delivery formulations of GSK’s Nucala in severe eosinophilic asthma

August 2, 2019
Medical Communications, Sales and Marketing Europe, GSK, Nucala, asthma, pharma

Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, …


Investigational Novartis therapy smashes primary and secondary endpoints in uncontrolled asthma

May 30, 2019
Research and Development Novartis, QVM149, asthma, pharma

Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …

Latest content